Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells

Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis

• Source: Angle PLC

UK-based liquid diagnostics company Angle completed another successful funding round worth £20m. 

The company issued approximately 17 million new shares at a price of 116 pence, a 6.83% discount over market price, the company announced on 25 June. The money will...

More from In Vitro Diagnostics

More from Diagnostics